AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 May 2022 04:00 PM
RNS
Director/PDMR Shareholding
09 May 2022 01:00 PM
RNS
Appointment of joint corporate brokers
06 May 2022 04:00 PM
RNS
Director/PDMR Shareholding
05 May 2022 07:10 AM
RNS
Enhertu approved in US for 2L HER2+ breast cancer
05 May 2022 07:05 AM
RNS
Farxiga HFpEF Phase III trial met primary endpoint
05 May 2022 07:00 AM
RNS
Ultomiris NMOSD Ph. III trial met primary endpoint
04 May 2022 07:00 AM
RNS
Imfinzi combo granted Priority Review for BTC
03 May 2022 03:00 PM
RNS
Total Voting Rights
29 Apr 2022 05:30 PM
RNS
Result of AGM
29 Apr 2022 07:05 AM
RNS
AstraZeneca plans new R&D centre in Massachusetts
29 Apr 2022 07:00 AM
RNS
First quarter 2022 results
28 Apr 2022 07:00 AM
RNS
Ultomiris approved in the US for adults with gMG
27 Apr 2022 07:00 AM
RNS
Enhertu granted BTD for HER2-low breast cancer
25 Apr 2022 07:00 AM
RNS
Tremelimumab US Priority Review for Imfinzi combo
19 Apr 2022 07:00 AM
RNS
Enhertu granted Priority Review for HER2m NSCLC
01 Apr 2022 03:00 PM
RNS
Total Voting Rights
29 Mar 2022 07:00 AM
RNS
Ondexxya approved in Japan for FXai reversal
28 Mar 2022 07:00 AM
RNS
Evusheld approved in the EU for COVID-19
25 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
24 Mar 2022 06:00 PM
RNS
Evusheld Positive EU CHMP Opinion
24 Mar 2022 07:00 AM
RNS
Update on CALLA Phase III trial for Imfinzi
23 Mar 2022 11:00 AM
RNS
Notice of AGM
17 Mar 2022 07:00 AM
RNS
Settlement of patent litigation for Ultomiris
14 Mar 2022 07:05 AM
RNS
Lynparza approved in US for early breast cancer
14 Mar 2022 07:00 AM
RNS
Update on US review of Fasenra in nasal polyps
09 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
07 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
01 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
01 Mar 2022 03:00 PM
RNS
Total Voting Rights
01 Mar 2022 07:00 AM
RNS
AstraZeneca and Neurimmune close deal for NI006
23 Feb 2022 07:00 AM
RNS
Filing of Form 20-F with SEC
22 Feb 2022 11:00 AM
RNS
Chair succession planning update and Annual Report
21 Feb 2022 07:00 AM
RNS
Enhertu improves PFS and OS in HER2-low BC
16 Feb 2022 07:00 AM
RNS
Saphnelo approved in EU for SLE
15 Feb 2022 07:00 AM
RNS
Lynparza combo delays progression risk in prostate
11 Feb 2022 03:30 PM
RNS
Director/PDMR Shareholding
10 Feb 2022 07:00 AM
RNS
AZN: Full year and Q4 2021 results
01 Feb 2022 03:00 PM
RNS
Total Voting Rights
19 Jan 2022 07:05 AM
RNS
Imfinzi improves survival in biliary tract cancer
19 Jan 2022 07:00 AM
RNS
Imfinzi combo shows unprecedented survival in HCC
17 Jan 2022 07:00 AM
RNS
Enhertu granted Priority Review for breast cancer
07 Jan 2022 07:00 AM
RNS
AstraZeneca and Neurimmune sign deal for NI006
05 Jan 2022 07:00 AM
RNS
Transfer of rights to Eklira, Duaklir completed
04 Jan 2022 03:00 PM
RNS
Total Voting Rights
29 Dec 2021 07:00 AM
RNS
AstraZeneca and Ionis close eplontersen deal
21 Dec 2021 07:00 AM
RNS
Ultomiris accepted for FDA Priority Review for gMG
20 Dec 2021 07:05 AM
RNS
Tezspire approved in the US for severe asthma
20 Dec 2021 07:00 AM
RNS
Saphnelo recommended for EU approval for SLE
15 Dec 2021 03:00 PM
RNS
Director/PDMR Shareholding
09 Dec 2021 07:00 AM
RNS
Evusheld US FDA EUA
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100